Alliance Pharma announce a proposed final dividend payment of 1.074p per share, giving a total dividend of 1.610p (2019: 0.536p)
Other financial highlights include:
Strong performance from Consumer Healthcare brands, which now account for over two thirds of Group see-through revenues
o Kelo-cote™ revenues up 12%
o Nizoral™ see-through revenues up 4%
o See-through revenues* overall up 1% to £93.0m (2019: £92.4m)
o Statutory revenues up 2% to £85.3m (2019: £83.7m)
Prescription Medicine revenues down 14% to £44.5m (2019: £51.9m), reflecting delays in routine treatments as a result of COVID-19
Group see-through revenue in total down 5% (down 5% CCY*) to £137.5m (2019: £144.3m)
Group statutory revenues down 4%, to £129.8m (2019: £135.6m)
Substantial US acquisition completed in December 2020, bringing a highly successful and fast-growing brand, Amberen™, into the Group, and creating scale in the Group's US operations
Underlying profit before tax up 2% to £33.5m (2019: £32.9m)
Reported profit before tax down 58% to £13.0m (2019: £31.1m), due to non-cash impairment and amortisation charges, and acquisition costs relating to the Biogix Inc acquisition
Group leverage post acquisition of Biogix Inc at 2.43 times, up from 1.48 times at December 2019; leverage expected to decrease to below 2.0 times during 2021
Free cash flow very strong at £34.1m, helped by favourable movements in net working capital
Cash generated from operations up 19% to £46.4m (2019: £39.0m)
